Recursion Has Opened 13 Sites for REC-994 Trial

February 15, 2023 –Recursion Pharmaceuticals has twelve US sites enrolling cavernous malformation patients in Phase 2 of their REC-994 Sycamore trial. This is the first industry-sponsored trial of a medicine for cerebral cavernous malformations, a massive milestone toward better treatments.

The most recent site to open is Emory University in Atlanta.  Please visit our website’s REC-994 Trial Information page for the complete list of open enrollment sites and inclusion/exclusion criteria.